Food allergy upstart Allergen Research Corporation raised an $80 million B round to get its lead candidate into late-stage development, pushing ahead with a treatment for peanut allergies.
Malvern, PA-based PhaseBio rounded up $40 million in Series C money to pursue its R&D dreams in the diabetes arena, bringing in pharma giant AstraZeneca as a backer in the process.
Canton, MA's Collegium Pharmaceutical put together a $50 million D round to ferry its abuse-discouraging opioid drug onto the market.
The health-focused joint venture set up by GE Healthcare and Intel has teamed with Xavier University to create a permanent testing laboratory. Intel-GE Care Innovations will use the site to test remote patient monitoring and communication technologies.
Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.
South San Francisco's Tricida raised $30 million in Series B cash to take its chronic kidney disease treatment into clinical trials, with venture capital giant OrbiMed leading the round.
Upstart cancer drug developer Aura Biosciences has rounded up $21 million for its Series B, attracting a large group of backers and keeping former Genzyme CEO and ubiquitous biotech investor Henri Termeer in the game.
Harvard chemistry professor Andrew Myers says he's made a breakthrough that can greatly expand a class of antibiotics, forming the foundation for his latest startup: Macrolide Pharmaceuticals. And the biotech is launching today with $22 million in venture cash from an impressive group of venture backers.
For more than a year now, NEA general partner David Mott has helmed Mersana Therapeutics, a Cambridge, MA-based biotech that has been working on next-gen antibody-drug conjugates. But this morning he's handing the reins over to longtime biotech vet Anna Protopapas (while remaining chairman) after organizing a $35 million B round that will be announced later this morning.
Israeli-American biotech Chiasma has raised $70 million in Series E cash, moving on from an aborted collaboration with Roche and rolling toward FDA approval with a treatment for the hormone disorder acromegaly.